BASF's TrinamiX Files Patent Lawsuit Against Apple: A Divestment Play, Not An Investment Inflection

BASF's biometric subsidiary trinamiX filed a patent infringement lawsuit against Apple today — the same German chemical company that announced in January it's considering selling trinamiX off.

The plaintiff is trinamiX Sensing LLC, the U.S. arm based in Austin, Texas. The complaint, filed September 3 in a federal court under 35 U.S.C. §100, alleges Apple's facial recognition technology infringes trinamiX's patents. The specific patent numbers and the court venue aren't yet public in the filing docket, but the subject is unmistakable: the same family of infrared dot-projection and liveness detection that powers Face ID.

The filing timing tells you more than the patent claims will. trinamiX has sat on the edges of BASF's empire since 2015, holding 800+ patents in biometric imaging and employing roughly 200 people in Ludwigshafen, Germany. Its core technology — beam profile analysis, which uses infrared light to map facial geometry and distinguish real skin from silicone, latex, or photographs — overlaps directly with the approach Apple built Face ID on. But after a decade of work, trinamiX's addressable market has been Android phones and automotive keyless entry. Apple's ecosystem has been a closed loop.

Until today, that closed loop was just out of reach.

trinamiX's technology works the way most people assume facial recognition already does. An infrared camera, a flood illuminator, and a dot projector — all mounted invisibly behind an OLED display — project a pattern of light onto the user's face. Algorithms analyze how the pattern deforms across three dimensions and, critically, how the material reflects infrared wavelengths. Living skin has a distinctive beam profile. Silicone masks, printed photos, and deepfake videos don't match.

This is not a marginal improvement on standard 2D facial recognition. It's essentially the same architecture Apple shipped with the iPhone X in 2017: structured infrared light, 3D mapping, liveness detection. Apple's TrueDepth camera projects approximately 30,000 invisible dots; trinamiX uses a dual 940 nm VCSEL array to achieve the same mapping through a single optical path. The differences are engineering choices, not different paradigms.

trinamiX's claimed advantage has been liveness detection that goes beyond geometry. Apple's system primarily maps the shape of a face; trinamiX adds material property analysis so it can identify not just that something is a mask but what the mask is made of. In lab demonstrations, the sensor distinguished a silicone mask from a live face and a printed photo from skin. The company achieved a spoof acceptance rate of 0% across major biometric certification programs — FIDO, IIFAA, and the Android Biometric Security Test.

None of that means Apple is infringing a trinamiX patent. It means the two companies solved the same problem using variations on the same approach. That's where the legal question lives, and where the investor question doesn't.

Apple has been sued over its biometric security systems repeatedly. In 2021, Gesture Technology Partners claimed Face ID infringed five camera-related patents — the court granted Apple judgment. In October 2024, a Texas jury found in Apple's favor against Identity Security LLC's $360 million claim. In December 2025, an Australian federal court ruled Apple didn't infringe CPC Patent Technologies' biometric security patents. In February 2026, a Delaware court invalidated Immervision's patent claim against Apple using the single-means doctrine.

The pattern isn't perfect — Apple has lost patent cases before, including a $533 million verdict to Smartflash in 2015 — but the trajectory for facial recognition claims specifically has favored Apple. The company spent years building its own patent moat. Apple holds 40,000+ granted patents and 11,000+ applications, with dense coverage around the TrueDepth system and the authentication pipeline.

The more relevant pattern is what happens to patent lawsuits filed by companies being divested.

BASF announced on January 26, 2026 that trinamiX is non-core and the company is examining strategic options — restructuring, cost efficiency, value optimization, and potential sale of individual business areas. The managing director who oversaw trinamiX from inception, Dr. Ingmar Bruder, departed the same day. His successor, Dr. Lothar Laupichler, had never worked on trinamiX before taking over; he headed BASF's global electronic materials business.

Filing a lawsuit against Apple six months into a strategic review of whether to sell the company reads less like a technology dispute and more like a valuation play. A credible patent claim against a company of Apple's size adds a line item to any purchase price. Whether the claim is credible is a question for a federal court, not a multiple expansion.

Here's what investors should separate:

trinamiX's technology is real. The beam profile analysis approach, the 800+ patents, the FIDO and IIFAA certifications, the Qualcomm partnership that integrated the sensor into Snapdragon platforms — these are engineering assets, not marketing claims. trinamiX demonstrated under-display face authentication behind OLED displays, which is a harder hardware problem than Apple's notch, and the company solved it.

But the technology also exists inside BASF's non-core bucket for a reason. After eleven years and roughly 200 employees, trinamiX has not scaled its biometric business into a standalone revenue stream. Apple's Face ID, by contrast, authenticates the most valuable consumer electronics ecosystem on the planet and generates billions in device revenue every quarter. Apple reported 14% revenue growth and a 32.6% operating margin in its latest period, with 28.6% free cash flow margin.

A patent lawsuit against Apple does not change any of those numbers. The legal exposure from any single patent claim is a fraction of Apple's quarterly operating income, and the company has a demonstrated track record of defending against biometric patent assertions. Even a worst-case scenario — a multi-hundred-million-dollar verdict — is a rounding error against a company that generated over $10 billion in capex and $11 billion in inventory while running 71% return on invested capital.

The real question isn't whether Apple will pay. It's whether this lawsuit signals that trinamiX's patents are valuable enough to command a premium sale price, or whether they're a litigation asset that inflates the asking price for a business that can't generate the revenue on its own. For the reader evaluating Apple, the answer is neither — the lawsuit is noise against a company whose investment case turns on services margins, installed base dynamics, and product cycle timing. None of those are affected by a patent complaint from a subsidiary whose parent company doesn't know whether it wants to keep it.